SCHEMBL240002

SCHEMBL240002

c1ccc(CCC2CC[N]CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
CARM1 Q86X55 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
CTSC P53634 1/20 0.46
SLC18A2 Q05940 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365368 0.89 CTSS (0.44) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL2303549 0.89 SLC18A3 (0.50)
SCHEMBL7286855 0.87 CYP19A1 (0.46) MAOA
SCHEMBL8111557 0.85 CYP19A1 (0.47)
SCHEMBL8116499 0.85 CYP19A1 (0.47)
SCHEMBL1609623 0.85 MAOA (0.58) MAOAMAOBCARM1PRMT6CTSL
SCHEMBL1366084 0.82 LOXL2 (0.42)
SCHEMBL7756938 0.81 OPRM1 (0.58) MAOAMAOBCTSSCTSKSLC18A2
SCHEMBL705394 0.81 CTSS (0.56) MAOAMAOBCTSSCTSKSLC18A2
SCHEMBL3119884 0.81 MAOB (0.53) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099157-A1 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2009-04-16 US claimed
WO-2008100621-A2 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
EP-0917464-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1999-05-26 EP claimed
WO-1998004251-A1 USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION SANOFI (FR) 1998-02-05 WO claimed
EP-0232089-B1 QUINONE AMIDES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1991-03-13 EP claimed
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
EP-4213822-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS Therapeutics (FR) 2023-07-26 EP disclosed
CN-116437960-A Compounds for the treatment of viral infections 梅莱蒂奥斯治疗 2023-07-14 CN disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-5290934-A Benzoheterocyclic compounds OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-03-01 US disclosed
EP-0565132-A2 Benzoheterocyclic compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-10-13 EP disclosed
US-5212181-A 1-(3,4-dihydro-2-oxo-1H-quinolin-6-yl)-2-[4-(2-phenylethyl)piperidin-1-yl]et[4-(2-phenylethyl)piperidin-1-yl]ethanone, to their preparation and to their therapeutic application SYNTHELABO (FR) 1993-05-18 US disclosed
EP-0287951-A2 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-10-26 EP disclosed
EP-0236140-A2 Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-09-09 EP disclosed
US-4353826-A ANTITUBERCULAR ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1982-10-12 US disclosed
US-4261891-A BACTERICIDES, ANTITUBERCULAR AGENTS CIBA-GEIGY CORPORATION (US) 1981-04-14 US disclosed
US-4005077-A DERIVATIVES OF RIFAMYCIN S OR SV CIBA-GEIGY CORPORATION (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MAOA 3731/4885MAOB 3191/4885CARM1 3322/4885
US-20090099157-A1 TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S CTSS, CTSE, CTSK MAOA 3540/4885MAOB 2816/4885CARM1 4032/4885
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS ACE, HAVCR2, FURIN MAOA 2452/4885MAOB 1872/4885CARM1 2570/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MAOA 3731/4885MAOB 3191/4885CARM1 3322/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS MAOA 3731/4885MAOB 3191/4885CARM1 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.